INNO — Innocan Pharma Income Statement
0.000.00%
- CA$70.17m
- CA$64.68m
- $13.66m
- 42
- 22
- 24
- 20
Annual income statement for Innocan Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0.008 | 0.196 | 2.56 | 13.7 |
Cost of Revenue | |||||
Gross Profit | — | 0.003 | 0.121 | 2.11 | 12 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 3 | 4.73 | 7.68 | 8.82 | 17.5 |
Operating Profit | -3 | -4.72 | -7.48 | -6.27 | -3.8 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -3.33 | -9.95 | -10.1 | -3.89 | -4.03 |
Provision for Income Taxes | |||||
Net Income After Taxes | -3.33 | -9.95 | -10.1 | -3.89 | -4.25 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -3.33 | -9.95 | -10 | -3.76 | -4.7 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -3.33 | -9.95 | -10 | -3.76 | -4.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.028 | -0.061 | -0.045 | -0.015 | -0.018 |